Editas Medicine (NASDAQ: EDIT) is a clinical-stage biotechnology company that develops human therapeutics using CRISPR gene-editing technology. Revenue is generated primarily through collaboration and other research and development agreements rather than product sales, as the company has not yet commercialized any therapy. Editas competes in the CRISPR gene-editing space against CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics, and numerous other biotechnology and pharmaceutical companies pursuing gene-editing approaches for conditions including hemoglobinopathies and hyperlipidemia. The company discontinued clinical development of its ex vivo reni-cel program, its most advanced candidate, and as of the 10-K filed March 9, 2026, was operating at a net loss with accrued research and development expenses of $9.7 million as of December 31, 2025. Gilmore O'Neill serves as President and Chief Executive Officer.
- Revenue model
- Collaboration and other research and development revenues, reported for fiscal years ended December 31, 2025 and December 31, 2024. No product sales revenue is disclosed. The company expenses research and development costs as incurred and operates at a net loss.
- Products and services
- CRISPR-based gene-editing therapies in research and development, including programs targeting hemoglobinopathies and hyperlipidemia. The ex vivo reni-cel program was the primary clinical-stage asset and was discontinued as of the FY2025 10-K filing. The platform uses CRISPR Cas9 and Cas12a technology.
- Customers and end markets
- Collaboration partners in the pharmaceutical and biotechnology sector. End markets targeted by pipeline programs include hemoglobinopathies and hyperlipidemia. No commercial product customers are disclosed in the filing excerpts.
- Value-chain role
- Drug developer. Editas licenses CRISPR intellectual property from the Broad Institute under the Cpf1 License Agreement and other agreements, conducts internal research and development, and relies on third-party vendors for research services. It does not manufacture or commercialize approved products as of the filing date.
- Geographic exposure
- No specific geographic revenue breakdown is disclosed in the filing excerpts. The filing references regulatory frameworks in the United States, European Union, and United Kingdom in the context of potential future product approvals.
- Competitors
- CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics, Vertex, Sanofi, Eli Lilly, AccurEdit Therapeutics, Scribe Therapeutics, Tune Therapeutics, Yoltech Therapeutics, EmendoBio, nChroma Bio, Ensoma, Genetix Biotherapeutics, Kamau Therapeutics, Orna Therapeutics, Reforgene Medicine, BRL Medicine, Tessera Therapeutics, Arsenal Biosciences, AvenCell Therapeutics, Caribou Biosciences, Century Therapeutics, Excision Biotherapeutics, Sarepta Therapeutics, ToolGen, EdiGene, eGenesis, ERS Genomics
